Mellitus is developing a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk and as a clinical trial test for pharmaceutical development. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM).

Medical Devices

Mellitus

Rick Saul

Kathy Welch

Michael Chorev

Christopher de Souza

Jing Shi

The Board Members at Mellitus provide strategic oversight, governance, and guidance to ensure the successful development and commercialization of the company's novel diagnostic tests. They bring diverse expertise to shape the company’s vision, support executive decisions, and oversee financial and operational health, with a particular emphasis on the lead product candidate for Gestational Diabetes Mellitus (GDM).

Board Members

About

Team members

Other teams at Mellitus

Leadership Team